- Home
- IGD vs DCTH Comparison
IGD vs DCTH Comparison
Compare IGD & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGD
- DCTH
- Stock Information
- Founded
- IGD N/A
- DCTH 1988
- Country
- IGD United States
- DCTH United States
- Employees
- IGD N/A
- DCTH N/A
- Industry
- IGD Trusts Except Educational Religious and Charitable
- DCTH Medical/Dental Instruments
- Sector
- IGD Finance
- DCTH Health Care
- Exchange
- IGD Nasdaq
- DCTH Nasdaq
- Market Cap
- IGD 456.6M
- DCTH 394.9M
- IPO Year
- IGD N/A
- DCTH N/A
- Fundamental
- Price
- IGD $5.86
- DCTH $11.38
- Analyst Decision
- IGD
- DCTH Strong Buy
- Analyst Count
- IGD 0
- DCTH 4
- Target Price
- IGD N/A
- DCTH $24.00
- AVG Volume (30 Days)
- IGD 215.3K
- DCTH 960.4K
- Earning Date
- IGD 01-01-0001
- DCTH 08-04-2025
- Dividend Yield
- IGD 9.15%
- DCTH N/A
- EPS Growth
- IGD N/A
- DCTH N/A
- EPS
- IGD N/A
- DCTH N/A
- Revenue
- IGD N/A
- DCTH $53,850,000.00
- Revenue This Year
- IGD N/A
- DCTH $162.10
- Revenue Next Year
- IGD N/A
- DCTH $32.97
- P/E Ratio
- IGD N/A
- DCTH N/A
- Revenue Growth
- IGD N/A
- DCTH 1068.87
- 52 Week Low
- IGD $4.60
- DCTH $7.17
- 52 Week High
- IGD $5.26
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- IGD 55.39
- DCTH 32.02
- Support Level
- IGD $5.75
- DCTH $10.95
- Resistance Level
- IGD $5.85
- DCTH $11.71
- Average True Range (ATR)
- IGD 0.05
- DCTH 0.59
- MACD
- IGD 0.00
- DCTH -0.05
- Stochastic Oscillator
- IGD 71.43
- DCTH 7.95
About IGD Voya Global Equity Dividend and Premium Opportunity Fund
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.